305 related articles for article (PubMed ID: 11857495)
1. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.
Kinnula VL; Lehtonen S; Sormunen R; Kaarteenaho-Wiik R; Kang SW; Rhee SG; Soini Y
J Pathol; 2002 Mar; 196(3):316-23. PubMed ID: 11857495
[TBL] [Abstract][Full Text] [Related]
2. Peroxiredoxins in breast carcinoma.
Karihtala P; Mäntyniemi A; Kang SW; Kinnula VL; Soini Y
Clin Cancer Res; 2003 Aug; 9(9):3418-24. PubMed ID: 12960131
[TBL] [Abstract][Full Text] [Related]
3. Characterization of neural cell types expressing peroxiredoxins in mouse brain.
Jin MH; Lee YH; Kim JM; Sun HN; Moon EY; Shong MH; Kim SU; Lee SH; Lee TH; Yu DY; Lee DS
Neurosci Lett; 2005 Jun; 381(3):252-7. PubMed ID: 15896479
[TBL] [Abstract][Full Text] [Related]
4. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.
Park JH; Kim YS; Lee HL; Shim JY; Lee KS; Oh YJ; Shin SS; Choi YH; Park KJ; Park RW; Hwang SC
Respirology; 2006 May; 11(3):269-75. PubMed ID: 16635084
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of peroxiredoxin in human breast cancer.
Noh DY; Ahn SJ; Lee RA; Kim SW; Park IA; Chae HZ
Anticancer Res; 2001; 21(3B):2085-90. PubMed ID: 11497302
[TBL] [Abstract][Full Text] [Related]
6. Variable overoxidation of peroxiredoxins in human lung cells in severe oxidative stress.
Lehtonen ST; Markkanen PM; Peltoniemi M; Kang SW; Kinnula VL
Am J Physiol Lung Cell Mol Physiol; 2005 May; 288(5):L997-1001. PubMed ID: 15626747
[TBL] [Abstract][Full Text] [Related]
7. Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma.
Soini Y; Kallio JP; Hirvikoski P; Helin H; Kellokumpu-Lehtinen P; Kang SW; Tammela TL; Peltoniemi M; Martikainen PM; Kinnula VL
APMIS; 2006 May; 114(5):329-37. PubMed ID: 16725008
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling.
Cox AG; Winterbourn CC; Hampton MB
Biochem J; 2009 Dec; 425(2):313-25. PubMed ID: 20025614
[TBL] [Abstract][Full Text] [Related]
9. Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis.
Kinnula VL; Lehtonen S; Kaarteenaho-Wiik R; Lakari E; Pääkkö P; Kang SW; Rhee SG; Soini Y
Thorax; 2002 Feb; 57(2):157-64. PubMed ID: 11828047
[TBL] [Abstract][Full Text] [Related]
10. Antisense of human peroxiredoxin II enhances radiation-induced cell death.
Park SH; Chung YM; Lee YS; Kim HJ; Kim JS; Chae HZ; Yoo YD
Clin Cancer Res; 2000 Dec; 6(12):4915-20. PubMed ID: 11156252
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure and solution NMR dynamics of a D (type II) peroxiredoxin glutaredoxin and thioredoxin dependent: a new insight into the peroxiredoxin oligomerism.
Echalier A; Trivelli X; Corbier C; Rouhier N; Walker O; Tsan P; Jacquot JP; Aubry A; Krimm I; Lancelin JM
Biochemistry; 2005 Feb; 44(6):1755-67. PubMed ID: 15697201
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of peroxiredoxin II confers resistance to cisplatin.
Chung YM; Yoo YD; Park JK; Kim YT; Kim HJ
Anticancer Res; 2001; 21(2A):1129-33. PubMed ID: 11396151
[TBL] [Abstract][Full Text] [Related]
13. The function of peroxiredoxins in plant organelle redox metabolism.
Dietz KJ; Jacob S; Oelze ML; Laxa M; Tognetti V; de Miranda SM; Baier M; Finkemeier I
J Exp Bot; 2006; 57(8):1697-709. PubMed ID: 16606633
[TBL] [Abstract][Full Text] [Related]
14. Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma.
Soini Y; Kahlos K; Puhakka A; Lakari E; Säily M; Pääkkö P; Kinnula V
Br J Cancer; 2000 Oct; 83(7):880-6. PubMed ID: 10970689
[TBL] [Abstract][Full Text] [Related]
15. High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.
Kuusisto ME; Haapasaari KM; Turpeenniemi-Hujanen T; Jantunen E; Soini Y; Peroja P; Bloigu R; Karihtala P; Kuittinen O
J Clin Pathol; 2015 Jul; 68(7):552-6. PubMed ID: 25935550
[TBL] [Abstract][Full Text] [Related]
16. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma.
Park JJ; Chang HW; Jeong EJ; Roh JL; Choi SH; Jeon SY; Ko GH; Kim SY
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1196-202. PubMed ID: 19251091
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of peroxiredoxin subtypes in human brain cell types.
Sarafian TA; Verity MA; Vinters HV; Shih CC; Shi L; Ji XD; Dong L; Shau H
J Neurosci Res; 1999 Apr; 56(2):206-12. PubMed ID: 10494109
[TBL] [Abstract][Full Text] [Related]
18. Peroxiredoxin VI in human respiratory system.
Chuchalin AG; Novoselov VI; Shifrina ON; Soodaeva SK; Yanin VA; Barishnikova LM
Respir Med; 2003 Feb; 97(2):147-51. PubMed ID: 12587965
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
Filho AL; Baltazar F; Bedrossian C; Michael C; Schmitt FC
Diagn Cytopathol; 2007 Dec; 35(12):786-91. PubMed ID: 18008346
[TBL] [Abstract][Full Text] [Related]
20. Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells.
Shen C; Nathan C
Mol Med; 2002 Feb; 8(2):95-102. PubMed ID: 12080185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
